Eptinezumab

艾普奈珠单抗

Report date: 2025/10/23 09:27:19

Base Information

Drug NameEptinezumab
Drug Alias Name依普奈珠单抗EptinezumabumEptinezumab-jjmrVyeptiALD-403
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCalcitonin gene-related peptide antagonists
TargetsCalcitonin gene-related peptide
Therapy Area/IndicationsPost-Traumatic HeadacheHeadache Disorders, SecondaryCluster Headache +[4] 
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/02/21
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesH. Lundbeck A/SAlder Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesLundbeck Seattle Biopharmaceuticals IncSunnybrook Health Sciences CentreVetter Pharma-Fertigung Gmbh & Co Kg +[5] 
Inactive CompaniesAlder Biopharmaceuticals Inc
Active IndicationsPost-Traumatic HeadacheHeadache Disorders, SecondaryCluster Headache +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG